[1] Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394:64-80.
[2] Wei KR, Zheng RS, Zhang SW, Liang ZH, Li ZM, Chen WQ. Nasopharyngeal carcinoma incidence and mortality in China, 2013. Chin J Cancer. 2017;36:90.
[3] Huang J, Fogg M, Wirth LJ, Daley H, Ritz J, Posner MR, Wang FC, Lorch JH. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma. Cancer. 2017;123:2642-2650.
[4] Lam WKJ, Chan JYK. Recent advances in the management of nasopharyngeal carcinoma. F1000Res. 2018;7.
[5] Liu SH, Chuang WC, Lam W, Jiang Z, Cheng YC. Safety surveillance of traditional Chinese medicine: current and future. Drug Saf. 2015;38:117-28.
[6] Fu J, Wang Z, Huang L, Zheng S, Wang D, Chen S, Zhang H, Yang S. Review of the botanical characteristics, phytochemistry, and pharmacology of Astragalusmembranaceus (Huangqi). Phytother Res. 2014;28:1275-83.
[7] Gao J, Liu ZJ, Chen T, Zhao D. Pharmaceutical properties of calycosin, the major bioactive isoflavonoid in the dry root extract of Radix astragali. Pharm Biol. 2014;52:1217-22.
[8] Zhang D, Wang S, Zhu L, Tian Y, Wang H, Zhuang Y, Li Y, Wang D. Profiling of hepatocellular carcinoma cell cycle regulating genes targeted by calycosin. Biomed Res Int. 2013;2013:317926.
[9] Chen J, Zhao X, Li X, Wu Y. Calycosin induces apoptosis by the regulation of ERβ/miR-17 signaling pathway in human colorectal cancer cells. Food Funct. 2015;6:3091-7.
[10] Zhou R, Wu K, Su M, Li R. Bioinformatic and experimental data decipher the pharmacological targets and mechanisms of plumbagin against hepatocellular carcinoma. Environ Toxicol Pharmacol. 2019;70:103200.
[11] Li R, Ma X, Song Y, Zhang Y, Xiong W, Li L, Zhou L. Anti-colorectal cancer targets of resveratrol and biological molecular mechanism: Analyses of network pharmacology, human and experimental data. J Cell Biochem. 2019;120:11265-11273.
[12] Pan Q, Zhou R, Su M, Li R. The Effects of Plumbagin on Pancreatic Cancer: A Mechanistic Network Pharmacology Approach. Med Sci Monit. 2019;25:4648-4654.
[13] Wu K, Wei P, Liu M, Liang X, Su M. To reveal pharmacological targets and molecular mechanisms of curcumol against interstitial cystitis. J Adv Res. 2019;20:43-50.
[14] Xiao H, Qin X, Wan J, Li R. Pharmacological Targets and the Biological Mechanisms of Formononetin for Alzheimer's Disease: A Network Analysis. Med Sci Monit. 2019;25:4273-4277.
[15] Li R, Guo C, Tse WKF, Su M, Zhang X, Lai KP. Metabolomic analysis reveals metabolic alterations of human peripheral blood lymphocytes by perfluorooctanoic acid. Chemosphere. 2019;239:124810.
[16] Li R, Qin X, Liang X, Liu M, Zhang X. Lipidomic characteristics and clinical findings of epileptic patients treated with valproic acid. J Cell Mol Med. 2019;23(9):6017-6023.
[17] Zhou R, Liu M, Liang X, Su M, Li R. Clinical features of aflatoxin B1-exposed patients with liver cancer and the molecular mechanism of aflatoxin B1 on liver cancer cells. Environ Toxicol Pharmacol. 2019;71:103225.
[18] Szadvari I, Krizanova O, Babula P. Athymic nude mice as an experimental model for cancer treatment. Physiol Res. 2016;65:441-453.
[19] Huang W, Su L, Zhang X, Xu X, Li R. Endocrinological characterization of pancreatic ducts in HFD and HGD fed mice. J Cell Biochem. 2019;120:16153-16159.
[20] Xu X, Guo C, Liang X, Li R, Chen J. Potential biomarker of fibroblast growth factor 21 in valproic acid-treated livers. Biofactors. 2019;45:740-749.
[21] Guo C, Wu K, Liang X, Liang Y, Li R. Infliximab clinically treating ulcerative colitis: A systematic review and meta-analysis. Pharmacol Res. 2019;148:104455. .
[22] Petersson F. Nasopharyngeal carcinoma: a review. Semin Diagn Pathol. 2015;32:54-73.
[23] Lee VH, Lam KO, Chang AT, Lam TC, Chiang CL, So TH, Choi CW, Lee AW. Management of Nasopharyngeal Carcinoma: Is Adjuvant Therapy Needed? J Oncol Pract. 2018;14:594-602.
[24] Zhang DQ, Wang HB, Wang SF, Wang DQ. Research achievements on biological activities of calycosin. Zhongguo Zhong Yao Za Zhi. 2015;40:4339-45.
[25] Kong L, Li X, Wang H, He G, Tang A. Calycosin inhibits nasopharyngeal carcinoma cells by influencing EWSAT1 expression to regulate the TRAF6-related pathways. Biomed Pharmacother. 2018;106:342-348.
[26] Song CV, Teo SH, Taib NA, Yip CH. Surgery for BRCA, TP53 and PALB2: a literature review. Ecancermedicalscience. 2018;12:863.
[27] Yamamoto S, Iwakuma T. Regulators of Oncogenic Mutant TP53 Gain of Function. Cancers (Basel). 2018;11.
[28] Keller N, Ozmadenci D2, Ichim G3, Stupack D4. Caspase-8 function, and phosphorylation, in cell migration. Semin Cell Dev Biol. 2018;82:105-117.
[29] Bonney EA. Mapping out p38MAPK. Am J Reprod Immunol. 2017;77.
[30] Igea A, Nebreda AR. The Stress Kinase p38α as a Target for Cancer Therapy. Cancer Res. 2015;75:3997-4002.